About: • The United States (US) has witnessed dramatic increases in opioid-overdose mortality since 1999. The need for ready access to scientifically sound treatment for opioid use disorder (OUD) is urgent, but gold-standard agonist therapy is often inaccessible. • Drug courts should help to reduce barriers to OUD therapy by offering court-supervised treatment as an alternative to criminal prosecution for certain categories of drug offenses. • Many drug courts, however, reject including the opioid agonist methadone and partial agonist buprenorphine as treatment options, often because these medicines are seen as “another form of addiction”. • Many US drug courts have steered participants to extended-release naltrexone (XR-NTX), an opioid antagonist, sometimes offering only XR-NTX and no agonist therapies. XR-NTX is very expensive in the US market and also requires a period of abstinence before it can be initiated. • Drug courts overall have had limited success in improving access to OUD treatment and other health and social services needed to achieve significant reduction in overdose death.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: • The United States (US) has witnessed dramatic increases in opioid-overdose mortality since 1999. The need for ready access to scientifically sound treatment for opioid use disorder (OUD) is urgent, but gold-standard agonist therapy is often inaccessible. • Drug courts should help to reduce barriers to OUD therapy by offering court-supervised treatment as an alternative to criminal prosecution for certain categories of drug offenses. • Many drug courts, however, reject including the opioid agonist methadone and partial agonist buprenorphine as treatment options, often because these medicines are seen as “another form of addiction”. • Many US drug courts have steered participants to extended-release naltrexone (XR-NTX), an opioid antagonist, sometimes offering only XR-NTX and no agonist therapies. XR-NTX is very expensive in the US market and also requires a period of abstinence before it can be initiated. • Drug courts overall have had limited success in improving access to OUD treatment and other health and social services needed to achieve significant reduction in overdose death. Goto Sponge NotDistinct Permalink

An Entity of Type : fabio:Abstract, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	abstract
value	• The United States (US) has witnessed dramatic increases in opioid-overdose mortality since 1999. The need for ready access to scientifically sound treatment for opioid use disorder (OUD) is urgent, but gold-standard agonist therapy is often inaccessible. • Drug courts should help to reduce barriers to OUD therapy by offering court-supervised treatment as an alternative to criminal prosecution for certain categories of drug offenses. • Many drug courts, however, reject including the opioid agonist methadone and partial agonist buprenorphine as treatment options, often because these medicines are seen as “another form of addiction”. • Many US drug courts have steered participants to extended-release naltrexone (XR-NTX), an opioid antagonist, sometimes offering only XR-NTX and no agonist therapies. XR-NTX is very expensive in the US market and also requires a period of abstinence before it can be initiated. • Drug courts overall have had limited success in improving access to OUD treatment and other health and social services needed to achieve significant reduction in overdose death.
part of	United States drug courts and opioid agonist therapy: Missing the target of overdose reduction
is abstract of	United States drug courts and opioid agonist therapy: Missing the target of overdose reduction

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software